Trial Profile
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2017
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 06 Jun 2017 Long term follow up results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 18 Apr 2011 New trial record